This transgene consists of 2.4 kb of the 5' flanking DNA, exon 1, and intron 1 of the mouse proteolipid protein driving oligodendrocyte-specific expression of the Eif2alpha kinase effector domain of Eif2ak3 fused to a polypeptide containing two modified FK506 binding domains. The activity of the kinase is dependent on the FK506 dimerizing agent AP20187. RT-PCR and Western blot confirmed the expression of mRNA and protein in the CNS and oligodendrocytes, respectively. Seven lines were established.